Fluidigm Seeks Judgment in Response to Applied Biosystems Letter
Fluidigm’s BioMark System is based on microfluidics, in contrast to the thermal cycler makers, including Bio-Rad Laboratories and Stratagene, that Applied Biosystems has successfully sued in the past for infringement of this patent .
New York, NY 6/9/08—Fluidigm has filed a complaint for declaratory judgment and demand for jury trial in the US District Court Southern District of New York. In its filing, Fluidigm stated that the complaint is in response to a letter the company received from Applied Biosystems/Applera on June 4. The letter demanded that Fluidigm cease sale of the BioMark System for Genetic Analysis due to infringement of US Patent No. 6,814,934 (“Instrument for Monitoring Nucleic Acid Amplification”). Fluidigm stated in the filing,“that the danger that Applera will sue Fluidigm for infringement is real and imminent.” Neither Fluidigm or Applied Biosystems issued statements.
